Login / Signup

Improving the Delivery of Levodopa in Parkinson's Disease: A Review of Approved and Emerging Therapies.

Daniele UrsoKallol Ray ChaudhuriMubasher A QamarPeter Jenner
Published in: CNS drugs (2020)
Levodopa is the most effective drug for the treatment of Parkinson's disease, but its use as an oral medication is complicated by its erratic absorption, extensive metabolism and short plasma half-life. On long-term use and with disease progression, there is a high incidence of motor and non-motor complications, which remain a major clinical and research challenge. It is widely accepted that levodopa needs to be administered using formulations that result in good and consistent bioavailability and the physiologically relevant and continuous formation of dopamine in the brain to maximise its efficacy while avoiding and reversing 'wearing off' and dyskinesia. However, the physicochemical properties of levodopa along with its pharmacokinetic and pharmacodynamic profile make it difficult to deliver the drug in a manner that fulfils these criteria. In this review, we examine the problems associated with the administration of levodopa in Parkinson's disease and how the use of novel technologies and delivery devices is leading to a more consistent and sustained levodopa delivery with the aim of controlling motor function as well as non-motor symptoms.
Keyphrases
  • parkinson disease
  • deep brain stimulation
  • risk factors
  • adverse drug
  • emergency department
  • metabolic syndrome
  • uric acid
  • resting state
  • functional connectivity